(Q34098594)

31 July 2017

1 reference

title

Locoregional immunotherapy in cancer patients: review of clinical studies (English)

1 reference

31 July 2017

1 reference

C M van Herpen

1

1 reference

PubMed ID

11106110

31 July 2017

P H De Mulder

series ordinal

2

1 reference

31 July 2017

1 October 2000

1 reference

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

10

1 reference

31 July 2017

1229-1239

1 reference

Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)

31 July 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Where have all the T cells gone? Mechanisms of immune evasion by tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Mechanisms responsible for signaling and functional defects.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Signaling defects in T lymphocytes of patients with malignancy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Regional administration of lymphokine-activated killer cells can be superior to intravenous application

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Optimal regimes for local IL-2 tumour therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Local Administration Trials of Interleukin-2 for Head and Neck Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma multiforme.A preliminary report

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intrathecal injection of autologous leucocytes in glioblastoma: circulatory dynamics within the subarachnoid space and clinical results.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Preliminary trial of specific targeting therapy against malignant glioma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intrapleural natural beta interferon in the treatment of malignant pleural effusions

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Viral oncolysates in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-α or interferon-α plus chemotherapy in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferon

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Immunotherapy of malignancy by in vivo gene transfer into tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Inhalation of interleukin-2 combined with subcutaneous administration of interferon for the treatment of pulmonary metastases from renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Peripheral natural killer cell activity and intraperitoneal soluble p55 tumor necrosis factor receptor in patients with malignant ascites: two possible indicators for response to intraperitoneal combined tumor necrosis factor alpha and interferon ga

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

IL-2 perfusion to the liver augments the hepatic extraction rate of accompanying anticancer drugs

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008335318764

7 January 2021

Identifiers

DOI

10.1023/A:1008335318764

1 reference

31 July 2017

1 reference

PubMed ID

11106110